A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials

Biomarkers in Medicine

Volumn 8, Issue 6, 2014, Pages 893-911

  Cramarossa, Gemma ^a   Lee, Esther K ^a   Sivanathan, Lavarnan ^a   Georgsdottir, Soley ^a   Lien, Kelly ^a   Santos, Keemo Delos ^a   Chan, Kelvin ^a   Emmenegger, Urban ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

angiogenesis; antiangiogenic therapy; biomarkers; cancer; low dose metronomic chemotherapy; maximum tolerated dose chemotherapy; systematic literature analysis; thrombospondin 1; VEGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CAPECITABINE; CD133 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; INTERLEUKIN 8; IRINOTECAN; KI 67 ANTIGEN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PODOPLANIN; PROCARBAZINE; THROMBOSPONDIN 1; TROFOSFAMIDE; UFT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; PHARMACOLOGICAL BIOMARKER;

ANTIANGIOGENIC ACTIVITY; BRAIN TUMOR; BREAST TUMOR; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY; CIRCULATING ENDOTHELIAL CELL; CIRCULATING ENDOTHELIAL PROGENITOR CELL; COLORECTAL TUMOR; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; LOW DOSE METRONOMIC CHEMOTHERAPY; LOW DRUG DOSE; LUNG TUMOR; LYMPHOMA; MAINTENANCE CHEMOTHERAPY; MELANOMA; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; MAXIMUM TOLERATED DOSE; MEDLINE; METRONOMIC DRUG ADMINISTRATION;

ADMINISTRATION, METRONOMIC; BIOMARKERS, PHARMACOLOGICAL; HUMANS; MAXIMUM TOLERATED DOSE; MEDLINE;

EID: 84907278186     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.14     Document Type: Review

References (102)

1. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4(6), 423-436 (2004).
2. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7(8), 455-465 (2010).
3. Romiti A, Cox MC, Sarcina I et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother. Pharmacol. 72(1), 13-33 (2013).
4. Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov. Today 18(3-4), 193-201 (2013).
5. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur. J. Cancer 49(16), 3387-3395 (2013).
6. Mross K, Steinbild S. Metronomic anti-cancer therapy-an ongoing treatment option for advanced cancer patients. J. Cancer Ther. Res. 1(1), 32 (2012).
7. Fontana A, Bocci G, Galli L et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J. Am Geriatr. Soc. 58(5), 986-988 (2010).
8. Bottini A, Generali D, Brizzi MP et al. Randomized Phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 24(22), 3623-3628 (2006).
9. Crivellari D, Gray KP, Dellapasqua S et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast 22(2), 130-137 (2013).
10. Bocci G, Tuccori M, Emmenegger U et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 16(8), 1243-1252 (2005).
11. André N, Banavali S, Snihur Y. Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 14(6), e239-e248 (2013).
12. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res. 180, 165-183 (2010).
13. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007).
14. Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 69(17), 6978-6986 (2009).
15. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 69(17), 6987-6994 (2009).
16. Nars Ms KR. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 132(11), 2471-2478 (2013).
17. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67(8), 3560-3564 (2007).
18. Vives M, Ginesta MM, Gracova K et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int. J. Cancer 133(10), 2464-2472 (2013).
19. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350(17), 1713-1721 (2004).
20. Watanabe T, Sano M, Takashima S et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J. Clin. Oncol. 27(9), 1368-1374 (2009).
21. Koopman M SLH, Lieke HJ Simkens, Tije AJT et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the Phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol. 31,(Suppl.) Abstract 3502 (2013).
22. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14(22), 7554-7563 (2008).
23. Allegrini G, Di Desidero T, Barletta MT et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15(2), 275-286 (2012).
24. Bhatt RS, Merchan J, Parker R et al. A Phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116(7), 1751-1756 (2010).
25. Generali D, Bates G, Berruti A et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin. Cancer Res. 15(3), 1046-1051 (2009).
26. Generali D, Fox SB, Brizzi MP et al. Down-regulation ofphosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolicpathway by primary letrozole-based therapy in human breast cancer. Clin. Cancer Res. 14(9), 2673-2680 (2008).
27. Generali D, Buffa FM, Berruti A et al. Phosphorylated ERalpha,HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatmentresponse and resistance in patients with breast cancer. J. Clin. Oncol. 27(2), 227-234 (2009).
28. Briasoulis E, Pappas P, Puozzo C et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 15(20), 6454-6461 (2009).
29. Brizzi MP, Berruti A, Ferrero A et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A Phase II trial of the Piemonte oncology network. BMC Cancer 9, 388 (2009).
30. Buckstein R, Kerbel RS, Shaked Y et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin. Cancer Res. 12(17), 5190-5198 (2006).
31. Chen YM, Fan WC, Tsai CM et al. A Phase II randomized trial ofgefitinib alone or with tegafur/uracil treatment in patients with pulmonaryadenocarcinoma who had failed previous chemotherapy. J. Thorac. Oncol. 6(6), 1110-1116 (2011).
32. Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology (Amsterdam, The Netherlands) 17(Suppl. 1), S90-S92 (2012).
33. Colleoni M. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13(1), 73-80 (2002).
34. Mancuso P, Colleoni M, Calleri A et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2), 452-459 (2006).
35. Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oralcyclophosphamide and methotrexate plus or minus thalidomide in metastaticbreast cancer: antitumor activity and biological effects. Ann. Oncol.17(2), 232-238 (2006).
36. Sandri MT, Johansson HA, Zorzino L et al. Serum EGFR and serum HER-2/neuare useful predictive and prognostic markers in metastatic breast cancerpatients treated with metronomic chemotherapy. Cancer 110(3), 509-517 (2007).
37. Calleri A, Bono A, Bagnardi V et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 15(24), 7652-7657 (2009).
38. Dellapasqua S, Bertolini F, Bagnardi V et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26(30), 4899-4905 (2008).
39. Dellapasqua S, Bagnardi V, Bertolini F et al. Increased mean corpuscular volume of red bloodcells predicts response to metronomic capecitabine and cyclophosphamide incombination with bevacizumab. Breast 21(3), 309-313 (2012).
40. El-Arab LRE, Swellam M, El Mahdy MM. Metronomic chemotherapy in metastatic breast cancer: Impact on VEGF J. Egypt. Natl Canc. Inst. 24(1), 15-22 (2012).
41. Fontana A, Galli L, Fioravanti A, et al. Clinical and pharmacodynamic evaluation of metronomiccyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin. Cancer Res. 15(15), 4954-4962 (2009).
42. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J. Clin. Oncol. 26(1), 76-82 (2008).
43. Hsu CY, Shen YC, Yu CW et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J. Hepatol. 55(4), 858-865 (2011).
44. Kelley RK, Hwang J, Magbanua MJ et al. A Phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br. J. Cancer 109(7), 1725-1734 (2013).
45. Kesari S, Schiff D, Doherty L et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro. Oncol. 9(3), 354-363 (2007).
46. Khan OA, Blann AD, Payne MJ et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br. J. Cancer 104(12), 1822-1827 (2011).
47. Lansiaux A, Salingue S, Dewitte A, Clisant S, Penel N. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest. New Drugs 30(1), 403-404 (2012).
48. Loven D, Be'ery E, Yerushalmi R et al. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Acta Oncol. 47(1), 104-109 (2008).
49. Miscoria M, Tonetto F, Deroma L et al. Exploratory predictive andprognostic factors in advanced breast cancer treated with metronomicchemotherapy. Anticancer Drugs 23(3), 326-334 (2012).
50. Montagna E, Cancello G, Bagnardi V et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin. Breast Cancer 12(3), 207-214 (2012).
51. Ogata Y, Sasatomi T, Mori S et al. Significance ofthymidine phosphorylase in metronomic chemotherapy using CPT-11 anddoxifluridine for advanced colorectal carcinoma. Anticancer Res. 27(4C), 2605-2611 (2007).
52. Orlandi P, Fontana A, Fioravanti A et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br. J. Cancer 109(4), 957-964 (2013).
53. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer 101(12), 1986-1994 (2009).
54. Reichle A, Bross K, Vogt T et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101(10), 2247-2256 (2004).
55. Reichle A, Vogt T, Coras B et al. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized Phase II trial. Melanoma Res. 17(6), 360-364 (2007).
56. Robison NJ, Campigotto F, Chi SN et al. A Phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr. Blood Cancer 61, 636-642 (2013).
57. Ruan J, Martin P, Coleman M et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116(11), 2655-2664 (2010).
58. Shao YY, Lin ZZ, Chen TJ et al. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology 81(2), 98-103 (2011).
59. Shao YY, Lin ZZ, Hsu C et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 82(1), 59-66 (2012).
60. Steinbild S, Arends J, Medinger M et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a Phase II study. Onkologie 30(12), 629-635 (2007).
61. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J. Pediatr. Hematol. Oncol. 28(11), 720-728 (2006).
62. Walter B, Schrettenbrunner I, Vogelhuber M et al. Pioglitazone, etoricoxib, interferon-alpha, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective Phase II trial. Med. Oncol. 29(2), 799-805 (2012).
63. Wong NS, Buckman RA, Clemons M et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28(5), 723-730 (2010).
64. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3(5), 391-400 (2004).
65. Orlando L, Cardillo A, Ghisini R et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6, 225 (2006).
66. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci. USA 100(22), 12917-12922 (2003).
67. Hamano Y, Sugimoto H, Soubasakos MA et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64(5), 1570-1574 (2004).
68. Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother. Pharmacol. 58(3), 354-360 (2006).
69. Mancuso P, Calleri A, Bertolini F. Circulating endothelial cells and circulating endothelial progenitors. Recent Results Cancer Res 195, 163-170 (2012).
70. Kraan J, Sleijfer S, Foekens JA, Gratama JW. Clinical value of circulating endothelial cell detection in oncology. Drug Discov. Today 17(13-14), 710-717 (2012).
71. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295(5559), 1526-1528 (2002).
72. Emmenegger U, Francia G, Chow A et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1), 40-48 (2011).
73. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60(7), 1878-1886 (2000).
74. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105(8), R15-R24 (2000).
75. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105(8), 1045-1047 (2000).
76. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin. Cancer Res. 19(11), 2824-2827 (2013).
77. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 47(4), 617-623 (2001).
78. Hormbrey E, Gillespie P, Turner K et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis 19(8), 651-663 (2002).
79. Zaslavsky A, Baek KH, Lynch RC et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115(22), 4605-4613 (2010).
80. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8(11), 880-887 (2008).
81. Nowak DG, Amin EM, Rennel ES et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J. Biol. Chem. 285(8), 5532-5540 (2010).
82. Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev. 19(1-2), 167-172 (2000).
83. Norrby K. In vivo models of angiogenesis. J. Cell. Mol. Med. 10(3), 588-612 (2006).
84. Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327-338 (2009).
85. Norrby K. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth? APMIS 122(7), 565-579 (2013).
86. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19(4), 1195-1206 (2001).
87. Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol. 45(2), 144-155 (2006).
88. Albertsson P, Lennernas B, Norrby K. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 120(2), 147-156 (2012).
89. Munoz R, Man S, Shaked Y et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66(7), 3386-3391 (2006).
90. Fioravanti A, Canu B, Ali G et al. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur. J. Pharmacol. 619(1-3), 8-14 (2009).
91. Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 118(12), 949-957 (2010).
92. Rapisarda A, Uranchimeg B, Scudiero DA et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62(15), 4316-4324 (2002).
93. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl Acad. Sci. USA 106(7), 2353-2358 (2009).
94. Kim YJ, Lee HJ, Kim TM et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1alpha. Int. J. Cancer 132(1), 29-41 (2013).
95. Cerullo V, Diaconu I, Kangasniemi L et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19(9), 1737-1746 (2011).
96. Martin-Padura I, Marighetti P, Agliano A et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest. 92(7), 952-966 (2012).
97. Kummar S, Raffeld M, Juwara L et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin. Cancer Res. 17(15), 5123-5131 (2011).
98. Huijts CM, Santegoets SJ, Van Den Eertwegh AJ et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 11, 505 (2011).
99. Ladoire S, Mignot G, Dalban C et al. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the Phase III UNICANCER-PACS 01 trial. Ann. Oncol. 23(10), 2552-2561 (2012).
100. Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest. New Drugs 32(1), 47-59 (2013).
101. Kubisch R, Meissner L, Krebs S et al. A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl. Oncol. 6(1), 1-9 (2013).
102. Thoenes L, Hoehn M, Kashirin R et al. In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J. Proteomics 73(7), 1342-1354 (2010).